icon
An official government website affiliated with the Government of the Kingdom of Saudi Arabia.
icon Tue 20 Oct 2026
Beta version
icon
Official Saudi government website domains end with gov.sa

All official websites of government entities in the Kingdom of Saudi Arabia end with.gov.sa.

icon
Official Reliable websites use HTTPS

Ensure the website is using the HTTPS protocol.

icon

Registered with the Digital Government Authority under number:

20250831619
Suggestions

Drug Approvals

SFDA Approved Use
Bupivacaine Hydrochloride Anhydrous 0.5% is indicated in adults and children of all ages for intrathecal (subarachnoid) spinal anaesthesia for surgery (urological and lower limb surgery lasting 2–3 hours, abdominal
surgery lasting 45–60 minutes).
Bupivacaine Hydrochloride Anhydrous is a long-acting anaesthetic agent of the amide type. Bupivacaine has a rapid onset of action and long duration. The duration of analgesia in the T10–T12 segments is 2–3 hours.
Bupivacaine Hydrochloride Anhydrous produces a moderate muscular relaxation of the lower extremities lasting 2–2.5 hours. The motor blockade of the abdominal muscles makes the solution suitable for performance
of abdominal surgery lasting 45–60 minutes. The duration of the motor blockade does not exceed the duration of analgesia. The cardiovascular effects of bupivacaine are similar or less than those seen with other spinal agents. Bupivacaine is exceptionally well tolerated by all tissues with which it comes in contact.